特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

移植片対宿主病 (GvHD):アジア太平洋地域の疫学的予測 (2028年まで)

Graft-Versus-Host Disease: Epidemiology Forecast in Asia-Pacific Markets to 2028

発行 GlobalData 商品コード 929721
出版日 ページ情報 英文 44 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.99円で換算しております。
移植片対宿主病 (GvHD):アジア太平洋地域の疫学的予測 (2028年まで) Graft-Versus-Host Disease: Epidemiology Forecast in Asia-Pacific Markets to 2028
出版日: 2020年02月28日 ページ情報: 英文 44 Pages
概要

アジア太平洋地域の主要5ヶ国 (オーストラリア、中国、インド、日本、韓国) における移植片対宿主病 (GvHD) の発症件数は、2018年~2028年の間に8,794件から13,673件へと、年間平均 (AGR) 5.55%の速度で増加していくと予測されています。この増加は、この5ヶ国における移植手術が緩やかに上昇傾向にあることが一因となっています。また、aGvHDの発症件数は2018年の4,650例から2028年には7,212例に増加し、cGvHDの発症件数は2018年の4,144例から2028年には6,461例に増加する見込みです。

当レポートでは、アジア太平洋地域の主要5ヶ国 (オーストラリア、中国、インド、日本、韓国) における移植片対宿主病 (GvHD)の発症状況と今後の見通しについて分析し、疾患の特徴や現在のの発症状況、今後10年間の発症件数・有病件数の予測値などを調査しております。

第1章 目次

第2章 移植片対宿主病 (GvHD):エグゼクティブサマリー

第3章 疫学

  • 病気の背景
  • リスク要因と併存症
  • 世界市場の過去の動向
    • オーストラリア
    • 中国
    • インド
    • 日本
    • 韓国
  • 予測手法
    • 使用される情報源
    • 使用されない情報源
    • 予測の前提条件と方法
  • GvHDの疫学予測 (2018~2028年)
    • 最初の同種HSCT (造血幹細胞移植) の実施件数3年間有病者数
    • 最初の同種HSCTにおけるaGvHD (急性GvHD) の発症件数
    • 最初の同種HSCTにおけるcGvHD (慢性GvHD) の発症件数議論
    • aGvHD・cGvHDの発症件数:年齢別
    • aGvHD・cGvHDの発症件数:グレード別
    • aGvHD・cGvHDの発症件数:重症度別
    • aGvHDの診断済み発症件数:100日間の死亡率
    • cGvHDの発症件数:1年間の死亡率
    • aGvHDの3年間有病者数
    • cGvHDの3年間有病者数
  • 議論
    • 疫学的予測に関する考察
    • 分析の制限
    • 分析の強み

第4章 付録

図表

List of Tables

  • Table 1: Risk Factors for GvHD

List of Figures

  • Figure 1: 5GM, Diagnosed Incident Cases of GvHD in Diagnosed Incident Cases of First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018 and 2028
  • Figure 2: 5GM, Diagnosed Incidence of aGvHD per 100 First Allogeneic HSCT Cases, All Ages, Both
目次
Product Code: GDHCER234-20

GvHD is a common complication of allogeneic HSCT that occurs when the donated (graft) cells are rejected and attack the host's cells as foreign. GvHD can progress from mild to severe forms as either aGvHD or cGvHD. Both aGvHD and cGvHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes. The global distribution of GvHD is directly dependent on transplantation-related factors, including the donor type, the age of the donor and the recipient, the sex parity between the recipient and the donor, the pre-transplantation conditioning regimen, and the use of GvHD prophylaxis pre- and/or post-transplantation.

GlobalData epidemiologists utilized historical HSCT data available through country-wide registry reports in the 5GM to the best extent possible to arrive at a meaningful in-depth analysis and forecast for GvHD. In this analysis, GlobalData epidemiologists provided detailed, clinically relevant segmentations for the diagnosed aGvHD and cGvHD incident cases. Further, GlobalData epidemiologists used country-specific estimates using valid diagnostic criteria to present aGvHD and cGvHD prevalent, grades and mortality cases.

The following data describes epidemiology of GvHD cases. In 2018, the 5GM had 8,794 diagnosed incident cases of GvHD (aGvHD and cGvHD). This is expected to increase to 13,673 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of 5.55%. This increase is partly attributed to the moderately rising trend in incidence in transplantation in the 5GM. In the 5GM, the diagnosed incident cases of aGvHD will increase from 4,650 cases in 2018 to 7,212 cases in 2028, at an Annual Growth Rate (AGR) of 5.51% per year, and the diagnosed incident cases of cGvHD will increase from 4,144 cases in 2018 to 6,461 cases in 2028, at an AGR of 5.59% per year.

Scope

  • Graft Versus Host Disease (GvHD) Asia Pacific Epidemiology Report provides an overview of the risk factors and global trends of GvHD in the five growth markets (5GM: Australia, China, India, Japan, and South Korea).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 5GM: diagnosed incident cases of first allogeneic Hematopoietic stem cell transplantation (HSCT), acute GvHD (aGvHD), and chronic GvHD (cGvHD); diagnosed three-year prevalent cases of aGvHD and cGvHD; and diagnosed incident cases of aGvHD and cGvHD by grade and severity respectively. Additionally, 100-day mortality in aGvHD and one-year mortality cases in cGvHD is also included in this report.
  • The GvHD Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5GM.

Reasons to Buy

The GvHD Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global GvHD market.
  • Quantify patient populations in the global GvHD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the aGvHD grades and cGvHD severity stages that present the best opportunities for GvHD therapeutics in each of the markets covered.
  • Understand magnitude GvHD market by mortality rates and three-year prevalent cases.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Graft-Versus-Host Disease: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
    • 3.3.1 Australia
    • 3.3.2 China
    • 3.3.3 India
    • 3.3.4 Japan
    • 3.3.5 South Korea
  • 3.4 Forecast Methodology
    • 3.4.1 Sources Used
    • 3.4.2 Sources Not Used
    • 3.4.3 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for GvHD (2018-2028)
    • 3.5.1 Incident Cases of First Allogeneic HSCT
    • 3.5.2 Incident Cases of aGvHD in First Allogeneic HSCT
    • 3.5.3 Incident Cases of cGvHD in First Allogeneic HSCT
    • 3.5.4 Age-Specific Incident Cases of aGvHD and cGvHD
    • 3.5.5 Diagnosed Incident Cases of aGvHD by Grade
    • 3.5.6 Diagnosed Incident Cases of cGvHD by Severity
    • 3.5.7 100-Day Mortality in Diagnosed Incident Cases of aGvHD
    • 3.5.8 One-Year Mortality in Diagnosed Incident Cases of cGvHD
    • 3.5.9 Three-Year Diagnosed Prevalent Cases of aGvHD
    • 3.5.10 Three-Year Diagnosed Prevalent Cases of cGvHD
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of Analysis
    • 3.6.3 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer